Skip to main content

Table 1 Patient, tumor, and treatment-related characteristics of thymic tumor (n = 156)

From: Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery

Characteristic

Training Cohort(n = 116)

Validation Cohort(n = 40)

N

%

N

%

Gender

 Male

63

54.3

20

50.0

 Female

53

45.7

20

50.0

Age (years)

  ≤ 60

89

76.7

32

80.0

 >60

27

23.3

8

20.0

Smoking history

 Never

84

72.4

34

85.0

 Ever

32

27.6

6

15.0

Drinking history

 No

100

86.2

37

92.5

 Yes

16

13.8

3

7.5

Family history of tumor

 No

98

84.5

34

85.0

 Yes

18

15.5

6

15.0

Underlying diseases

 No

82

70.7

34

85.0

 Yes

34

29.3

6

15.0

Tumor size (cm)

  ≤ 6

65

56.0

24

60.0

 >6

51

44.0

16

40.0

pT stage

 T1

91

78.4

31

77.5

 T2–3

25

21.6

9

22.5

Masaoka stage

 I

61

52.6

15

37.5

 II-III

55

47.4

25

62.5

WHO stage

 A-AB

45

38.8

18

45.0

 B1-B3

60

51.7

17

42.5

 C

11

9.5

5

12.5

Myasthenia gravis,

 No

107

92.2

37

92.5

 Yes

9

7.8

3

7.5

tumor capsule status

 Incomplete

38

32.8

9

22.5

 Complete

78

67.2

31

77.5

Invasion of great vessels

 No

91

78.4

33

82.5

 Yes

25

21.6

7

17.5

ALB

  ≤ 40.8

29

25.0

7

17.5

 >40.8

87

75.0

33

82.5

GLB

  ≤ 28.8

58

50.0

6

15.0

 >28.8

58

50.0

34

85.0

A/G

  ≤ 1.5

54

46.6

18

45.0

 >1.5

62

53.4

22

55.0

NE

  ≤ 5.6

102

87.9

32

80.0

 >5.6

14

12.1

8

20.0

LY

  ≤ 2.5

28

24.1

8

20.0

 >2.5

88

75.9

32

80.0

NE/LY (NLR)

  ≤ 3.0

100

86.2

32

80.0

 >3.0

16

13.8

8

20.0

PLT

  ≤ 237

64

55.2

16

40.0

 >237

52

44.8

24

60.0

PLT/LY (PLR)

  ≤ 161.6

104

89.7

32

80.0

 >161.6

12

10.3

8

20.0

PLT/NE*LY (SII)

  ≤ 764.3

102

87.9

30

75.0

 >764.3

14

12.1

10

25.0

  1. NLR neutrophil-to-lymphocyte ratio, Hb hemoglobin, ALB albumin, BMI body mass index, NE neutrophil count, LY lymphocyte count, GLB globulin, SII systemic immune-inflammation Index, PLT platelet, PLR platelet-lymphocyte ratio, pT stage pathological T stage